VERAgene is the only non-invasive prenatal test that can simultaneously screen for aneuploidies, microdeletions and single gene diseases. The diseases screened by VERAgene are associated with moderate to severe phenotype with significant impact on the quality of life. By combining detection of aneuploidies and microdeletions with the screening of monogenic disorders, VERAgene provides a comprehensive solution to prospective parents.

WHAT SHOULD I ASK MY DOCTOR?

WHAT IS A NON-INVASIVE PRENATAL TEST (NIPT)?

It is a test that a pregnant woman can take to check for genetic conditions of the fetus before birth.

WHAT ARE GENETIC CONDITIONS?

Genetic conditions are caused by unwanted changes in the genome that happen during conception. Three types of genetic conditions are detected with the test:

  • aneuploidies are genetic conditions that occur when a chromosome has an extra copy (trisomy) or is missing a copy (monosomy)
  • microdeletions are genetic conditions caused by a small deletion in a specific region of a chromosome
  • single gene diseases are genetic conditions caused by mutations in a gene

How does it work?

During pregnancy, fetal cell-free DNA travels from placenta and circulates in the mother’s blood along with her own cell-free DNA. Cell-free DNA is isolated from the mother’s blood, and analysed with the father’s DNA sample to detect any potential genetic mutations using proprietary new generation technology and bioinformatics. The results of the screening test are then sent to the doctor who communicates them to the family with the appropriate counseling.

WHAT CONDITIONS CAN BE DETECTED?

VERAgene can detect trisomies of chromosomes 21, 18, 13, aneuploidies of X and Y chromosomes, DiGeorge syndrome, 1p36 deletion syndrome, Smith-Magenis syndrome and Wolf-Hirschhorn syndrome, and 50 monogenic diseases. VERAgene targets nearly 500 mutations on 50 genes to screen for 50 monogenic diseases. By combining detection of aneuploidies and microdeletions with the screening of monogenic disorders, VERAgene provides a comprehensive picture of the pregnancy using a single test. Click here to learn more about all the conditions screened by VERAgene.

AUTOSOMAL ANEUPLOIDIES

  • Down syndrome (Trisomy 21)
  • Edwards syndrome (Trisomy 18)
  • Patau syndrome (Trisomy 13)

SEX CHROMOSOME ANEUPLOIDIES

  • Turner syndrome (Monosomy X)
  • Triple X syndrome (Trisomy X)
  • Klinefelter syndrome (XXY)
  • Jacobs syndrome (XYY)
  • XXYY syndrome

MICRODELETIONS

  • DiGeorge syndrome (22q11.2)
  • 1p36 deletion syndrome
  • Smith-Magenis syndrome (17p11.2)
  • Wolf-Hirschhorn syndrome (4p16.3)

Monogenic disorders

IS THERE AN AGE LIMIT FOR VERAgene?

No. VERAgene can be done by pregnant women of all ages because it screens for genetic conditions that don’t have any maternal age-associated risk.

WHEN CAN I DO THE TEST?

VERAgene test can be done as early as the 10th week of gestation.

WHY SHOULD A PREGNANT WOMAN DO THE VERAgene TEST?

Unlike aneuploidies, the microdeletions and single gene diseases do not have a maternal age associated risk, chemical or ultrasound biomarkers that can help in early detection. The cumulative risk for the fetus to be affected by one of the genetic conditions screened by VERAgene is higher than 1 in 65 and could be higher in some ethnic populations where some of the conditions are more prevalent. VERAgene can accurately screen for these conditions to help parents take informed decisions about possible treatments and clinical management.

HOW CAN I TAKE THE VERAgene TEST?

  • BE AT LEAST 10 WEEKS PREGNANT
  • ASK YOUR DOCTOR ABOUT TAKING VERAgene
  • YOUR DOCTOR WILL COLLECT A BLOOD SAMPLE FROM YOU AND A BUCCAL SWAB FROM THE FATHER
  • THE SAMPLES WILL BE ANALYSED IN OUR LABORATORIES
  • THE TEST RESULTS WILL BE SENT TO YOUR DOCTOR IN 4-7 WORKING DAYS

FAQ

  • What is NIPT?

    NIPT is a screening test taken by a pregnant woman to check for genetic conditions of the fetus before birth. NIPT analyzes cell-free DNA in the mother’s blood to identify these genetic conditions. NIPT is important because it provides a safe and accurate way to test the baby before birth for genetic disorders, the most common of which is Down syndrome. Before the introduction of this revolutionary test, the options to test for Down syndrome were either screening methods like ultrasound combined with biochemical testing which have low accuracy (approximately 80-95%) or high accuracy prenatal diagnosis that uses invasive methods [e.g. amniocentesis or chorionic villi sampling (CVS)] which have 0.5% risk for miscarriage.

  • What are genetic conditions?

    The human genome is sorted into twenty-three pairs of chromosomes. Genetic conditions are caused by unwanted changes in the genome that happen during conception. There are three types of genetic conditions:

    • aneuploidies are genetic conditions that occur when a chromosome has an extra copy (trisomy) or is missing a copy (monosomy)
    • microdeletions are genetic conditions caused by the deletion of part of a chromosome
    • single gene diseases are genetic conditions caused by pathogenic alterations (mutations) in a gene

  • What is VERAgene comprehensive NIPT?

    VERAgene is the only non-invasive prenatal test that can simultaneously screen for aneuploidies, microdeletions and single gene diseases. The diseases screened by VERAgene are associated with moderate to severe phenotype with significant impact on the quality of life. These genetic diseases exhibit symptoms such as congenital anomalies, development delays, hearing loss, blindness, metabolic disorders, etc.

  • What genetic conditions can be detected by VERAgene?

    VERAgene can screen for trisomies such as Down syndrome, Edwards syndrome, Patau syndrome, sex chromosome aneuploidies, microdeletions such as DiGeorge syndrome, 1p36 deletion syndrome, Smith-Magenis syndrome and Wolf-Hirschhorn syndrome and 50 monogenic disorders such as beta thalassemia, cystic fibrosis, Tay-Sachs disease, Canavan disease, sickle cell anemia, familial Mediterranean fever, phenylketonurea, etc. By combining detection of aneuploidies and microdeletions with the screening of monogenic disorders, VERAgene provides a comprehensive picture of the pregnancy using a single test.

  • What are Down syndrome, Edwards syndrome and Patau syndrome?

    Down syndrome, Edwards syndrome and Patau syndrome are genetic disorders caused by chromosomal trisomies. Down syndrome is caused by an extra copy of chromosome 21 whereas Edwards syndrome and Patau syndrome are caused by an extra copy of chromosome 18 and chromosome 13, respectively. Down syndrome is characterized by intellectual impairment and congenital abnormalities. Down syndrome occurs approximately in 1 in 700 pregnancies but is more frequent in pregnancies in women over 35. Edwards syndrome and Patau syndrome are less common occurring in 1 in 3000 and 1 in 10000 pregnancies, respectively. Edwards and Patau syndromes are characterized by severe congenital abnormalities and rarely survive past the first year of life.

  • What are sex chromosome aneuploidies?

    Sex chromosome aneuploidies are genetic diseases caused by the presence or absence of a sex chromosome. The 23rd pair of chromosomes determine the sex of an individual. Women have two X chromosomes and men have one X and one Y chromosome. There are four major sex chromosome aneuploidies:

    • Turner syndrome is characterized by the presence of a single X chromosome.
    • Triple X syndrome is characterized by the presence of three X chromosomes.
    • Klinefelter syndrome is characterized by the presence of two X chromosomes and one Y chromosome.
    • Jacob syndrome is characterized by the presence of one X chromosome and two Y chromosomes.

  • What are microdeletions?

    Microdeletions are genetic conditions caused by the loss of a part of a chromosome. Microdeletions are characterized by congenital abnormalities and intellectual impairment. The severity of the symptoms varies depending on the size and location of the microdeletion. The most common microdeletion syndrome is DiGeorge syndrome which occurs approximately once in 1000 pregnancies. The prevalence of DiGeorge syndrome increases to 1 in 100 in pregnancies with major structural anomalies such as congenital heart disease.

  • What are monogenic disorders?

    Monogenic disorders are caused by mutations in a single gene. Such conditions can be either autosomal dominant which are caused when the mutation exists on only one chromosome, or autosomal recessive where the mutation needs to be present in both chromosomes. VERAgene analyses 500 mutations to detect 50 autosomal recessive monogenic disorders.

  • Why should expecting parents consider VERAgene?

    Unlike aneuploidies, microdeletions and single gene diseases do not have a maternal age associated risk, chemical or ultrasound biomarkers that can help in early detection. The cumulative risk for the fetus to have one of the monogenic conditions screened by VERAgene is 1 in 196, and is higher in some ethnic populations where some of the conditions are more prevalent. VERAgene can accurately screen for these conditions to help parents take informed decisions about possible treatments and clinical management.

  • I have other questions. Where can I find additional information?

    Please contact your doctor or healthcare provider for additional information.

Other Products

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!